- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Artroker is a nonsteroidal anti-inflammatory agent (NSAID). After ingestion, diacerein is rapidly absorbed from the gastrointestinal tract and is fully deacetylated to Rein. Simultaneous use of the drug with food increases bioavailability by 25%. Cmax of rhein in plasma is reached after 1.44 minutes. T1 / 2 of plasma is 255 minutes. The connection of rhein with albumin is almost 100%. With a single dose of 50 mg Cmax reaches 3.15 mg / l. With repeated use of the drug Cmax increases due to cumulation of the drug. Reina is excreted by the kidneys in unchanged form (20%) and as glucuronide (60%) and sulfate (20%). Rein penetrates the placental barrier and BBB.
Primary and secondary osteoarthritis.
1 capsule contains:
Active substance: Diacerein 50.0 mg
Excipients: lactose monohydrate, povidone, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide
Hard gelatin capsule (body): gelatin, water, brilliant blue dye, titanium dioxide, phloxin B dye, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium lauryl sulfate
Hard gelatin capsule (cap): gelatin, water, brilliant blue dye, titanium dioxide, quinoline yellow dye, phloxin B dye, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium lauryl sulfate
Diacerein is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Artroker||Micro Labs Ltd||India||capsules|
|Diaflex rompharm||K.O.Romparm Company S.R.L||Romania||capsules|
No customer reviews for the moment.
Dosage and Administration
Standard intake of 1 capsule 2 times a day (in the morning and in the evening, after meals). Capsules should be swallowed whole, not liquid, and drink water. The effect of the treatment should be expected in 2-4 weeks. Art broker is applied continuously for a long time or courses of at least 4 months. The duration of the break between treatments is set by the doctor.
With increased sensitivity to the components of the drug may experience allergic reactions of varying degrees, rash, itching. In the initial period of administration of the drug, phenomena from the alimentary system can take place temporarily: diarrhea, nausea, vomiting, and abdominal pain. In this case, the dose should be reduced to 1 capsule per day.
There may be an intense urine staining from yellow to brown (depending on pH), which does not require a dose reduction (withdrawal) of the drug.
Individual intolerance to the components of the drug Artroker or high sensitivity to anthraquinone drugs (for example, laxatives). Children's age (up to 18 years). Pregnancy, lactation. Severe hepatic or renal failure, intestinal obstruction, inflammatory bowel disease. Lactose intolerance, lactase deficiency, glucose galactose malabsorption.
The art broker is not recommended to be taken together with drugs that affect the consistency of the intestinal contents (for example, a large amount of fiber).
Antacids reduce the absorption of the drug. When taken concomitantly with antibiotics or chemotherapeutic drugs that affect the intestinal microflora, the frequency of intestinal adverse events may increase.
The duration of treatment, depending on the result achieved, can be long. In the period preceding the development of the therapeutic effect, Artroker can be taken simultaneously with non-narcotic analgesics and other nonsteroidal anti-inflammatory drugs. Periodic monitoring of blood parameters, liver enzymes, urine activity is necessary. When kidney function deteriorates, the doctor must decide to reduce the dose of the drug or cancel it.
With an overdose possible diarrhea, weakness. In case of overdose or accidental use of drugs by children, it is necessary to consult a doctor. Symptomatic treatment.
- Brand name: Artroker
- Active ingredient: Diacerein
- Dosage form: Capsules
- Manufacturer: Micro Labs Ltd
- Country of Origin: India
- Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial
- The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: A randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period
- Pharmacokinetics of diacerein in patients with liver cirrhosis
- Effect of oral diacerein (DAR) in an experimental hip chondrolysis model
- Isolation and structural elucidation of two impurities from a diacerein bulk drug
- Diacerein decreases TNF-α and IL-1β levels in peritoneal fluid and prevents Baker’s yeast-induced fever in young rats
- The true results of the ECHODIAH study with diacerein
- Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial
- Diacerein as a disease-modulating agent in osteoarthritis
- Anti-inflammatory and anti-peroxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation
- Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China
- Stability-indicating spectrophotometric and spectrodensitometric methods for the determination of diacerein in the presence of its degradation product
- Influence of renal function on the pharmacokinetics of diacerein after a single oral dose
- The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study
- Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1β-stimulated C-28/I2 chondrocytes
- Reply to the comment on: comparison between chondroprotective effects of glucosamine, curcumin and diacerein in IL-1ß-stimulated C-28/I2 chondrocytes
- Comment on: comparison between chondroprotective effects of glucosamine, curcumin and diacerein in IL-1β-stimulated C-28/I2 chondrocytes
- Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials
- Estimation of chondroitin sulfate as a biomarker in articular cartilage for treatment of osteoarthritis through oral diacerein loaded lipid nanoparticles in rat model
- Diacerein suppresses the increase in plasma nitric oxide in rat adjuvant-induced arthritis
- Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption
- P127 A systematic meta-analysis of clinical trials with diacerein in osteoarthritis
- P172 Diacerein in osteoarthritis — Results of a postmarketing surveillance project